Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Zepbound in the U.S. will have a list price of about US$1,000 a month, the same as Mounjaro, but U.S. medicare is prohibited from covering drugs specifically for weight loss.

Eli Lilly, the pharmaceutical company behind GLP-1 injection Zepbound, is working to bring its weight loss drug to the market in pill form. In an Aug. 7 earnings call, Eli Lilly C ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

The U.S. Food and Drug Administration has approved the use of another diabetes drug for chronic weight management in adults, regulators said Wednesday. Tirzepatide — Eli Lilly’s diabetes drug approved ...

Zepbound and Wegovy have other uses, but these aren’t addressed here. To learn more about the dosages for all uses of these drugs, see the Zepbound dosage article and Wegovy dosage article.

And since Lilly is making access to Zepbound far more achievable, I think it will begin acquiring many more customers. So even though shares of Eli Lilly are pricey, I still see the stock as a ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy.

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.